Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma
Based on the findings from the Phase II study (NCT04022343), neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic ccRCC. According to the results from the analysis, 17 patients with biopsy-proven clear-cell RCC were treated with neoadjuvant cabozantinib at a starting dose of 60 mg once per day for 12 weeks.
The results of this investigation revealed that all of the patients' tumors had shrunk. Five patients (29.4%) experienced a partial response, while 12 patients ...
